Notch3 Antibody Monoclonal

<strong>Notch3 Antibody Monoclonal</strong>_x000D_ <strong>Catalog number:</strong> B2010597_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 200 uL_x000D_ <strong>Molecular Weight or Concentration:</strong> na_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool in the study of Notch 3_x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> Monoclonal Anti-Notch3 antibody produced in rat, Anti-CADASIL, Anti-CASIL, anti-notch3 antibody_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Yu J, Siebel CW, Schilling L, Canalis E. An antibody to Notch3 reverses the_x000D_ skeletal phenotype of lateral meningocele syndrome in male mice. J Cell Physiol._x000D_ 2020 Jan;235(1):210-220._x000D_ _x000D_ 2: Katoh M, Katoh M. Precision medicine for human cancers with Notch signaling_x000D_ dysregulation (Review). Int J Mol Med. 2020 Feb;45(2):279-297._x000D_ 3: Varga J, Nicolas A, Petrocelli V, Pesic M, Mahmoud A, Michels BE, Etlioglu E,_x000D_ Yepes D, Häupl B, Ziegler PK, Bankov K, Wild PJ, Wanninger S, Medyouf H, Farin_x000D_ HF, Tejpar S, Oellerich T, Ruland J, Siebel CW, Greten FR. AKT-dependent NOTCH3_x000D_ activation drives tumor progression in a model of mesenchymal colorectal cancer._x000D_ J Exp Med. 2020 Oct 5;217(10):e20191515._x000D_ _x000D_ 4: Young KZ, Lee SJ, Zhang X, Cartee NMP, Torres M, Keep SG, Gabbireddy SR,_x000D_ Fontana JL, Qi L, Wang MM. NOTCH3 is non-enzymatically fragmented in inherited_x000D_ cerebral small-vessel disease. J Biol Chem. 2020 Feb 14;295(7):1960-1972._x000D_ _x000D_ 5: Machuca-Parra AI, Bigger-Allen AA, Sanchez AV, Boutabla A, Cardona-Vélez J,_x000D_ Amarnani D, Saint-Geniez M, Siebel CW, Kim LA, D'Amore PA, Arboleda-Velasquez_x000D_ JF. Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss_x000D_ in CADASIL. J Exp Med. 2017 Aug 7;214(8):2271-2282._x000D_ _x000D_ 6: Rosen LS, Wesolowski R, Baffa R, Liao KH, Hua SY, Gibson BL, Pirie-Shepherd_x000D_ S, Tolcher AW. A phase I, dose-escalation study of PF-06650808, an anti-Notch3_x000D_ antibody-drug conjugate, in patients with breast cancer and other advanced solid_x000D_ tumors. Invest New Drugs. 2020 Feb;38(1):120-130._x000D_ _x000D_ 7: Ghezali L, Capone C, Baron-Menguy C, Ratelade J, Christensen S, Østergaard_x000D_ Pedersen L, Domenga-Denier V, Pedersen JT, Joutel A. Notch3^ECD_x000D_ immunotherapy improves cerebrovascular responses in CADASIL mice. Ann Neurol._x000D_ 2018 Aug;84(2):246-259._x000D_ _x000D_ 8: Geles KG, Gao Y, Giannakou A, Sridharan L, Yamin TT, Zhang J, Karim R, Bard_x000D_ J, Piche-Nicholas N, Charati M, Maderna A, Lucas J, Golas J, Guffroy M, Pirie-_x000D_ Shepherd S, Roy M, Qian J, Franks T, Zhong W, O'Donnell CJ, Tchistiakova L,_x000D_ Gerber HP, Sapra P. NOTCH3-targeted antibody drug conjugates regress tumors by_x000D_ inducing apoptosis in receptor cells and through transendocytosis into ligand_x000D_ cells. Cell Rep Med. 2021 May 18;2(5):100279._x000D_ _x000D_ 9: Lu H, Jiang Z. Advances in antibody therapeutics targeting small-cell lung_x000D_ cancer. Adv Clin Exp Med. 2018 Sep;27(9):1317-1323._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/30873760/">10: Wu D, Zhang P, Ma J, Xu J, Yang L, Xu W, Que H, Chen M, Xu H. Serum_x000D_ biomarker panels for the diagnosis of gastric cancer. Cancer Med. 2019_x000D_ Apr;8(4):1576-1583. </a>_x000D_ _x000D_ <strong>Products Related to Notch3 Antibody Monoclonal</strong><a href="https://moleculardepot.com/product-category/Antibodies/">: Antibodies</a>